Clal Biotechnology Industries

What Clal Biotechnology Industries does

Clal Biotechnology Industries (TASE: CBI) is an Israeli life sciences investment holding company founded in 1998 and headquartered in Tel Aviv. The firm identifies and nurtures early- to late-stage ventures developing proprietary solutions to address unmet medical needs, spanning biotechnology, pharmaceuticals, diagnostics, and medical devices. CBI is majority-owned by Clal Industries Ltd., itself wholly owned by Access Industries, providing backing from one of Israel's leading diversified investment groups.

CBI's portfolio comprises approximately 13 companies, including NASDAQ-listed MediWound (MDWD, enzymatic therapeutics for tissue repair), Elicio Therapeutics (ELTX, cancer immunotherapy), FDNA (AI-powered facial analysis for genetic disorder diagnostics), Sight Diagnostics (point-of-care blood analysis), Pi-Cardia (non-implant heart valve repair), Colospan (colorectal surgery solutions), Biokine (stem cell mobilization for oncology), and the Anatomy Medical Technology Fund (early-stage medical devices). Cadent Therapeutics, a CNS-disorder treatment developer, was previously part of the portfolio and was acquired by Novartis. CBI's go-to-market is direct institutional investment rather than traditional sales; the firm collaborates with multinational pharmaceutical corporations and prominent investment funds to advance portfolio companies.

The firm operates with a lean internal team (1-10 employees) and is led by CEO Ofer Gonen, Chairman Avi Fischer, CFO Liat Nissan, and Medical Director Arnon Aharon, supported by a board that includes academic clinicians. Revenue mechanics derive from portfolio company growth, exits, and value realization rather than fee-based management income; no pricing structure is publicly disclosed, and the company's standalone top line is not separately reported in available source material.

Name

Clal Biotechnology Industries

Legal name

Clal Biotechnology Industries Ltd.

Website

https://cbi.co.il

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Clal Biotechnology Industries (TASE: CBI) is an Israeli life sciences investment holding company that manages a portfolio of approximately 13 biotechnology, pharmaceutical, diagnostics, and medical device companies addressing unmet medical needs.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Management

NAICS

All Other Financial Investment Activities (52399)

SIC

Finance Services (6199)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

Keywords

• Life sciences investment
• Venture capital management
• Biotechnology portfolio
• Medical technology investment
• Healthcare venture funding

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns and Portfolio Management: CBI generates returns through its investment portfolio of biotechnology and medical technology companies. The firm identifies and nurtures ventures that develop proprietary solutions to address unmet medical needs with substantial market potential. Returns are realized through portfolio company growth, exits, and value creation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Clal Biotechnology Industries (CBI) is a life sciences investment holding company that identifies, funds, and nurtures an international portfolio of approximately 13 biotechnology and medical technology companies. CBI provides strategic collaboration, hands-on leadership, and expert guidance to portfolio companies developing proprietary solutions for unmet medical needs across biotechnology, pharmaceuticals, diagnostics, and medical devices. Returns are realized through portfolio company growth, exits, and value creation.

Product overview

Clal Biotechnology Industries (TASE: CBI) is a life sciences investment company that manages a diversified portfolio of biotechnology and medical technology companies. Rather than a unified product platform, CBI's offering consists of investment management services overseeing approximately 13 portfolio companies spanning biotechnology, pharmaceuticals, diagnostics, and medical devices. The portfolio companies include MediWound (enzymatic therapeutics), FDNA (AI-powered genetic diagnostics), Elicio Therapeutics (cancer immunotherapy), Sight Diagnostics (point-of-care blood diagnostics), Colospan (colorectal surgery solutions), Pi-Cardia (heart valve repair), Biokine (stem cell mobilization), and others. These companies develop proprietary solutions addressing unmet medical needs, drawing on research from Israeli and US institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Clal Biotechnology Industries Investment Management Life sciences venture capital and investment management services, identifying and nurturing groundbreaking ventures that develop proprietary solutions for unmet medical needs. The firm manages an international portfolio of approximately 13 biotechnology companies across various growth stages from seed to maturity.
• FDNA AI-powered diagnostics company that uses computer vision and facial analysis technology for detecting genetic disorders and syndromes.
• MediWound Enzymatic therapeutics company focused on tissue repair solutions, publicly traded on NASDAQ (MDWD).
• Biokine Biotechnology company developing stem cell mobilization technology for cancer treatment applications.
• Elicio Therapeutics Cancer immunotherapy company publicly traded on NASDAQ (ELTX), developing proprietary immunotherapy candidates.
• Cadent Therapeutics CNS disorders treatment company acquired by Novartis, previously part of the CBI portfolio.
• Sight Diagnostics Point-of-care blood diagnostics company providing rapid laboratory-grade blood analysis solutions.
• Colospan Medical technology company developing novel solutions for colorectal surgery procedures.
• Pi-Cardia Medical device company developing non-implant heart valve repair solutions for patients with valvular heart disease.
• Anatomy Medical Technology Fund Medical technology investment fund focused on early-stage medical device companies.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Partnerships

One partnership is on record.

• Multinational Pharmaceutical CorporationscoreStrategic or Co-development PartnerCBI portfolio companies actively collaborate with multinational pharmaceutical corporations, fostering strategic partnerships to drive growth and innovation in life sciences development.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• HBM Healthcare Investments: Publicly listed Swiss investment company that invests globally in private and public human medicine companies across all development stages. Directly comparable to CBI as a listed, single-sector life sciences investment vehicle with a diversified portfolio of biotech and medtech holdings.
• SV Health Investors: Specialist healthcare and life sciences venture firm investing across biotech, medtech, and digital health from seed to growth. Comparable business model and active value-add approach to portfolio companies.
• Medicxi: European life sciences investment firm managing single-asset and diversified biotech funds from seed to growth stages. Comparable in therapeutic focus, stage coverage, and value-add model of partnering closely with portfolio management teams.
• BioLight Life Sciences Investments: Israeli life sciences investment company listed on TASE, focused on identifying and nurturing biomedical technologies. Comparable to CBI in geography, listing venue, and stage-diversified life sciences portfolio strategy.
• Hadasit Bio-Holdings: Israeli publicly listed holding company that commercializes medical innovations originating from Hadassah Medical Center, with a portfolio of biotech and medtech companies. Directly comparable as another Israel-headquartered, TASE-listed life sciences investment vehicle.

Broad incumbents

• Novo Holdings: Holding and investment company responsible for managing the wealth of the Novo Nordisk Foundation, with large-scale life sciences venture and growth investments globally. A much larger, established incumbent operating a similar life sciences investment mandate.
• OrbiMed Advisors: One of the world's largest healthcare-dedicated investment firms, operating private equity, venture, and public-equity strategies across biotech and medtech. A broader, more established incumbent in the same niche CBI targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clal Biotechnology Industries